Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.
Midcaps hammered in February, plunge up to 30%. IREDA, Delhivery among biggest losers
Midcap stocks faced heavy selling in February, dropping up to 30% as investors booked profits and cut losses. Global concerns, including Trump’s tariff threats and
March 1, 2025